Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)

Inclusion Criteria: * Patients with advanced solid tumors (metastatic or local) unresponsive to standard therapy, progressed on standard therapy, or no standard therapy exists. No limit to the number of prior treatment regimens * Patients may be fully active without physical restrictions, ambulatory with restrictions on strenuous physical activity, or ambulatory and capable of self-care but not work activities (i.e., Eastern Cooperative Oncology Group performance status of greater than or equal to 2) * Demonstrates adequate organ function (liver, kidneys, hematologic) Exclusion Criteria: * Chemotherapy or radiation therapy within 2 weeks of dosing; or unresolved side effects(s) from prior treatment regimen * Participation in an investigational study within 14 days of dosing * Primary central nervous system tumor * Active brain or spinal cord metastases. Patients who completed a course of therapy for CNS metastases may be eligible if considered clinically stable for 3 months prior to study entry * Symptoms from fluid in the abdomen or around the lungs * Requires certain drugs or other products known to be metabolized by the liver enzyme CYP3A4